Physician profile
Jonardi Handoko
NPI 1780664581
$1,911.73
in general payments reported to CMS, 2019-2025
13 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $66.78 · 2021: $291 · 2022: $578 · 2023: $414 · 2024: $92.33 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.55 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $642.48 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $340.77 | 2019-2023 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $188.48 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $185.73 | 2019-2023 | Lokelma |
| Akebia Therapeutics INC | $123.27 | 2024-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $94.91 | 2022-2023 | Jynarque |
| Ardelyx, INC. | $80.58 | 2023-2025 | Ibsrela |
| Amgen INC. | $76.56 | 2022-2025 | Krystexxa, Parsabiv, Tavneos |
| Sanofi-Aventis U.S. LLC | $67.50 | 2019 | |
| Travere Therapeutics, INC. | $43.09 | 2023 | |
| Mallinckrodt Hospital Products INC. | $26.74 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.00 | 2023 | |
| Vifor Pharma, INC. | $20.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonardi Handoko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.